CAREERS-CHIASMAPHARMA.ICIMS.COM

chiasmapharma.com

About Chiasma | Chiasma

http://www.chiasmapharma.com/node/1

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Chiasma is dedicated to improving the lives of patients who face challenges associated with existing treatments for their rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE. The company is now conducting an additional international Phase 3 trial on Mycapssa in acromegaly designed to support a potential Marketing Authorization Application with the European Medicines Agency. Chias...

chiasmapharma.com

Chiasma's Product Development Effort | Chiasma

http://www.chiasmapharma.com/transformational-products

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Chiasma's Product Development Effort. Chiasma is focused on improving the lives of patients by developing and ultimately commercializing oral therapies that eliminate the significant limitations and burdens generally associated with therapies that are currently only available as injections. The company's proprietary Transient Permeability Enhancer (TPE. Chiasma’s lead investigational candidate, Mycapssa.

chiasmapharma.com

Our Mission | Chiasma

http://www.chiasmapharma.com/transformational-mission

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. At Chiasma, we are focused on improving the lives of patients suffering from orphan diseases by developing and ultimately commercializing novel oral therapies that are available today only by injection. We are guided every day by our strongly held values:. For the patients we serve. In applying our proprietary Transient Permeability Enhancer (TPE. Terms of Use (Updated).

chiasmapharma.com

Octreotide Capsules | Chiasma

http://www.chiasmapharma.com/node/16

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Chiasma's octreotide capsules, which are are conditionally trade named Mycapssa. Are being developed for the treatment of acromegaly, a rare, debilitating disease typically caused by a benign tumor of the pituitary gland that releases excess growth hormone (GH), leading to excess growth of certain parts of the body. For Investigational Use Only. Product Not Available for Commercial Distribution.

chiasmapharma.com

Publications | Chiasma

http://www.chiasmapharma.com/publications

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial. J Clin Endocrinol Metab. 2015; doi: 10.1210/jc.2014-4113. A Novel Suspension Formulation Enhances Intestinal Absorption of Macromolecules Via Transient and Reversible Transport Mechanisms. J Clin Endocrinol Metab. Terms of Use (Updated).

ir.chiasmapharma.com

Clinical Advisors | Chiasma

http://www.ir.chiasmapharma.com/clinical-advisors

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Our team of advisors includes academic and clinical leaders with world-renowned reputations in the field of endocrinology. Shlomo Melmed, MD. Senior Vice President, Academic Affairs, Dean of. Christian J. Strasburger, MD. Professor of Medicine, Chief, Division of.

ir.chiasmapharma.com

Chiasma's Product Development Effort | Chiasma

http://www.ir.chiasmapharma.com/products

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Chiasma's Product Development Effort. Chiasma is focused on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. The company's proprietary Transient Permeability Enhancer (TPE ) technology platform is designed to enable the intestinal absorption of molecules that would otherwise have limited intestinal bioavailability.

ir.chiasmapharma.com

Patients & Families | Chiasma

http://www.ir.chiasmapharma.com/patients-families

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. At Chiasma, we are focused on helping patients who suffer from conditions that require chronic injections, by developing product candidates based on our proprietary Transient Permeability Enhancer (TPE ) technology platform. We are developing octreotide capsules for the potential treatment of acromegaly in adults with acromegaly.

ir.chiasmapharma.com

About Acromegaly | Chiasma

http://www.ir.chiasmapharma.com/about-acromegaly

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Common features of acromegaly are facial changes, intense headaches, joint pain, impaired vision and enlargement of the hands, feet, tongue and internal organs. Serious health conditions associated with the progression of acromegaly include type 2 diabetes, hypertension, respiratory disorders and cardiac and cerebrovascular disease.

chiasmapharma.com

About Chiasma | Chiasma

http://www.chiasmapharma.com/chiasma

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Chiasma is dedicated to improving the lives of patients who face challenges associated with existing treatments for their rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE. The company is now conducting an additional international Phase 3 trial on Mycapssa in acromegaly designed to support a potential Marketing Authorization Application with the European Medicines Agency. Chias...